SCHEMBL3300481

SCHEMBL3300481

COc1ccc(CNc2nc3c(c(=O)n2-c2ccccc2)CN(C(=O)Nc2cc(F)ccc2F)CC3)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRLHR P49683 5/20 0.45
CLPP Q16740 1/20 0.40
TP53 P04637 2/20 0.40
HTR7 P34969 2/20 0.39
ALDH1A1 P00352 4/20 0.39
MAPT P10636 3/20 0.39
MEN1 O00255 2/20 0.39
TSHR P16473 2/20 0.39
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 2/20 0.39
ALOX15 P16050 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39
RECQL P46063 1/20 0.39
USP2 O75604 1/20 0.38
PKM P14618 1/20 0.38
MAPK1 P28482 1/20 0.38
PDE5A O76074 1/20 0.38
HPGD P15428 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3296568 0.95 PRLHR (0.45) PRLHRCLPPTP53ALDH1A1MAPT
SCHEMBL3300259 0.94 PRLHR (0.44) PRLHRCLPPTP53ALDH1A1MAPT
SCHEMBL3297657 0.94 PRLHR (0.44) PRLHRCLPPHTR7ALDH1A1MAPT
SCHEMBL3296765 0.93 PRLHR (0.46) PRLHRCLPPALDH1A1MAPTMEN1
SCHEMBL3297793 0.92 PRLHR (0.50) PRLHR
SCHEMBL3297279 0.91 PRLHR (0.49) PRLHRCLPPALDH1A1MAPTMEN1
SCHEMBL3296948 0.90 PRLHR (0.44) PRLHRCLPPHTR7ALDH1A1MAPT
SCHEMBL3301087 0.90 RECQL (0.47) PRLHRCLPPALDH1A1MAPTMEN1
SCHEMBL3298474 0.89 PRLHR (0.45) PRLHRCLPPALDH1A1MAPTKDM4E
SCHEMBL3300866 0.89 PRLHR (0.44) PRLHRCLPPALDH1A1MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232282-B2 Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-07-31 US disclosed
US-20100093771-A1 Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-04-15 US disclosed
EP-2078719-A1 COMPOUND HAVING BICYCLIC PYRIMIDINE STRUCTURE AND PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2009-07-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093771-A1 Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same GART, MGAT2, MGAT1 PRLHR 3093/4885CLPP 4670/4885TP53 3665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.